Global pharmaceutical companies are moving into China to use the large amount of data from the country ’s 1.3 billion population generated by the US / China trade agreement , as pharmaceuticals are not involved . Sanofi has opened its first Asian research centre in Chengdu , Pfizer subsidiary Upjohn has opened its first office in Shanghai and Shionogi is developing new drugs in China ahead of the US , Europe and its home market in Japan . Upjohn, the off-patent drug unit of U.S.-based Pfizer, established its global headquarters in Shanghai in China ’s pharmaceutical market increased to $ 5000 in 2018 , 240 % up from 2008 . The country has also joined an international quality specification organisation for the US , Europe and Japan .
Global pharmaceutical companies are moving into China to use the large amount of data from the country ’s 1.3 billion population generated by the US / China trade agreement , as pharmaceuticals are not involved . Sanofi has opened its first Asian research centre in Chengdu , Pfizer subsidiary Upjohn has opened its first office in Shanghai and Shionogi is developing new drugs in China ahead of the US , Europe and its home market in Japan . China ’s pharmaceutical market increased to $ 5000 in 2018 , 240 % up from 2008 . The country has also joined an international quality specification organisation for the US , Europe and Japan .